Tedizolid is Safe in Liver Disease
Tedizolid requires no dose adjustment in patients with hepatic impairment, including those with moderate (Child-Pugh B) or severe (Child-Pugh C) liver disease. This makes it an excellent antibiotic choice when treating infections in patients with compromised liver function.
Pharmacokinetic Evidence in Hepatic Impairment
The FDA drug label provides definitive guidance based on formal pharmacokinetic studies 1. Following a single 200 mg oral dose of tedizolid in patients with moderate (Child-Pugh B, n=8) or severe (Child-Pugh C, n=8) hepatic impairment, there were no clinically meaningful changes in mean tedizolid Cmax or AUC compared to matched healthy controls.
More specifically, research data shows that tedizolid AUC increased only approximately 22% in moderate hepatic impairment and 34% in severe hepatic impairment 2. These modest increases are not considered clinically significant and do not warrant dose modification.
Why Tedizolid is Safe in Liver Disease
The safety profile stems from tedizolid's unique metabolic pathway:
- Minimal hepatic oxidative metabolism: Tedizolid does not undergo significant Phase 1 hepatic CYP450 metabolism 1
- Alternative elimination pathway: Conjugation occurs via sulfotransferase (SULT) isoforms rather than traditional hepatic enzymes 1
- Predominantly fecal excretion: 82% eliminated in feces, only 18% in urine, primarily as an inactive sulfate conjugate 1
- No accumulation risk: The drug's elimination pathway remains functional even in severe cirrhosis
Clinical Application
For all degrees of hepatic impairment (Child-Pugh A, B, or C):
- Use standard dose: 200 mg once daily (oral or IV)
- No monitoring adjustments needed beyond standard infection parameters
- No increased risk of hepatotoxicity compared to patients with normal liver function
Comparison to Other Antibiotics
This contrasts sharply with many other antimicrobials that require significant dose adjustments in liver disease. For example, the guidelines note that protease inhibitors show markedly increased exposures in severe hepatic impairment and are contraindicated in Child-Pugh C patients 3. Similarly, simeprevir shows 2.4-fold higher AUC in Child-Pugh B and 5.2-fold higher in Child-Pugh C, making it not recommended or contraindicated in these populations 3.
Important Caveats
While tedizolid is safe in hepatic impairment, clinicians should:
- Monitor for the drug's known adverse effects (headache, nausea, diarrhea) which occur regardless of liver function 4
- Be aware that tedizolid is a reversible MAO inhibitor, though clinically significant interactions are rare 1
- Consider that tedizolid inhibits BCRP transporter, potentially increasing exposure to BCRP substrates like rosuvastatin by approximately 70% 1
The bottom line: Tedizolid's favorable pharmacokinetic profile makes it one of the safest antibiotic options for patients with any degree of liver disease, requiring no dose adjustment even in decompensated cirrhosis 1, 2.